A Case Report of Metastatic Gastric Cancer Treated with Pembrolizumab during Pregnancy
Open Access
- 26 June 2024
- journal article
- research article
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 51 (5) , 493-499
Abstract
Introduction: Immune checkpoint inhibitors are extensively used in present-day clinical practice for treating many types of cancers at different stages. To date, there are scarce data on the use of immunotherapy in pregnancy. Immune-related adverse events are a typical consequence of this therapy miming autoimmune diseases. Case Presentation: A 35-year-old woman (G1P0) diagnosed with gastric carcinoma underwent neoadjuvant chemotherapy followed by surgery. During follow-up, axillary metastasis was discovered, radiotherapy failed, and consequently immunotherapy was started. Concurrently, pregnancy ensued. Despite potential risks, the patient opted to continue immunotherapy and the pregnancy. At 31 weeks, fetal bowel dilation was noted. Subsequently, the fetus also developed fetal growth restriction. A cesarean section was performed at 35 weeks. The newborn required repeated bowel resections for necrotizing enterocolitis, necessitating extensive medical intervention. The mother continues pembrolizumab treatment with a positive response. Conclusion: To the best of our knowledge, this might constitute a possible case of a fetal immune-related adverse event after immunotherapy in utero exposure.Keywords
This publication has 34 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Immunotherapy for cancer treatment during pregnancyThe Lancet Oncology, 2021
- Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancyEuropean Journal of Cancer, 2018
- Immune Checkpoint Inhibitor Toxicity in 2018JAMA, 2018
- Interferon gamma in cancer immunotherapyCancer Medicine, 2018
- Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and ManagementCurrent Neurology and Neuroscience Reports, 2018
- An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 InhibitorsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2016
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodiesBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2009
- The function of programmed cell death 1 and its ligands in regulating autoimmunity and infectionNature Immunology, 2007